Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Table 5 Univariable Cox regression analysis of survival

	PFS		OS
	HR	p Value	HR	p Value
Age		0.0065		0.0162
Tumor size before therapy
cT1 vs. cT2	7.621 (1.024–56.707)	0.0473	n.s.
Nodal status after therapy
yNo vs. yN2, yN3	3.377 (1.283–8.890)	0.0137	4.104 (1.201–14.027)	0.0243
Response to NACT
Partial response vs. no response	3.107 (1.157–8.344)	0.0245	n.a.
Complete response vs. no response	16.974 (1.971–145.174)	0.0099	n.s.

HR hazard ratio, NACT neoadjuvant chemotherapy, OS overall survival, PFS progression-free survival; n.a. not applicable, n.s. not significant.

ISSN: 1465-542X